

Non-renounceable Entitlement Offer – Extension of Closing Date

30 March 2023: Osteopore Limited (ASX: OSX) (**Osteopore** or **Company**), refers to its announcement titled ‘Non-Renounceable Entitlement Offer’ dated 13 March 2023, in relation to the non-renounceable pro rata offer to Eligible Shareholders to raise up to A\$2,633,617 (before costs) through the offer of one (1) new fully paid ordinary share in the Company (**Share**) for every four (4) Shares held by Eligible Shareholders on 16 March 2023 (**Record Date**) at an issue price of A\$0.085 per new Share (**Entitlement Offer**).

Capitalised terms used, but not defined, in this announcement have the meaning given to them in the Prospectus released to ASX on 13 March 2023.

The Company advises that the Closing Date of the Entitlement Offer and Top-Up Offer has been extended to 5.00pm (AEST) on 17 April 2023, to ensure that all Eligible Shareholders have an opportunity to participate.

The revised indicative timetable for the Offers is set out below.

Event	Date
Lodgement of Appendix 3B with ASX	10 March 2023 (after market close)
Lodgement of Prospectus with the ASIC and ASX	10 March 2023 (after market close)
Ex-date	15 March 2023
Record Date for determining Entitlements	16 March 2023
Despatch of Prospectus and Application Form	21 March 2023
Opening date for the Offers	21 March 2023
Company holds General Meeting and ASX notified of results of the General Meeting	31 March 2023
Last day to extend the Closing Date of the Offers (other than the Shortfall Offer and Lead Manager Offer)	Before noon (Sydney time) on 12 April 2023
Closing Date of the Offers (other than the Shortfall Offer and Lead Manager Offer) as at 5.00pm (AEST)*	17 April 2023
Securities under the Entitlement Offer, Top-Up Offer and Placement Option Offer quoted on a deferred settlement basis	18 April 2023
Announcement of results of Entitlement Offer and Top-Up Offer	21 April 2023

Issue date and lodgement of Appendix 2A with ASX applying for quotation of Shares and Quoted Options subscribed for under the Entitlement Offer, Top-Up Offer and Placement Option Offer	Before noon (Sydney time) on 24 April 2023
Quotation of Securities issued under the Entitlement Offer, Top-Up Offer and Placement Option Offer*	26 April 2023
Issue of Remaining Shortfall Securities under Shortfall Offer (if any) and Lead Manager Options under the Lead Manager Option Offer	By no later than 17 July 2023

* All dates (other than the date of the Prospectus and the date of lodgement of the Prospectus with ASIC and ASX) are indicative only. The Directors may extend the Closing Date in respect of the Entitlement Offer and Top-Up Offer by giving at least 3 Business Days' notice to ASX prior to the Closing Date. As such the date the Securities issued under the Offers are expected to commence trading on ASX may vary.

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

+65 9011 7009

Mark_Leong@osteopore.com

About Osteopore Limited

Osteopore Ltd is an Australian and Singapore based medical technology company commercialising a range of products specifically engineered to facilitate natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants. Our 3D printer technology is not available in the market and unique to Osteopore.